Back to search results

Pain Control After Total Knee Replacement

This study is comparing two different nerve block medications to help manage pain after total knee replacement surgery. Researchers want to see if a combination of bupivacaine, Dexamethasone sodium phosphate, and Methylprednisolone acetate works better than bupivacaine and Liposomal Bupivacaine for pain relief. They will measure your pain scores and how much pain medication you use for up to 48 hours after surgery. The study also aims to see if one combination leads to a better overall recovery. You may be able to join if you are 18 or older, having a single total knee replacement, and meet certain health criteria. The study plans to enroll 250 people, but its current status is unclear.

Study design
This is a phase 2, double-blinded, and randomized clinical trial. It will involve 250 participants undergoing total knee replacement surgery.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your pain will be measured on Day 1 and Day 2 after surgery. Opioid consumption will be tracked from the end of anesthesia until discharge, up to 48 hours.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05279092

Yale Steroid Enhanced Versus Exparel Nerveblock TKA RCT Study

Recruiting
PHASE2Ages 18+InterventionalSupportive care
Yale University
~250 participants
Updated 2026-07-23 on ClinicalTrials.gov
What's tested:Bupivacaine-Liposomal BupivacaineBupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Postoperative Knee Pain Score
Measured over Day 1 and Day 2
+1 more outcome measured

Conditions

Total Knee Replacement
Knee Arthroplasty

Explore related trials

Osteoarthritis

Where it's being run

2 sites across 1 states
Connecticut2

Study leadership

  • Jinlei Li, MD PhD · PRINCIPAL_INVESTIGATOR · Yale University

Who to contact

Jinlei Li, MD PhD
[email protected]
475-434-4038
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

American Society of Anesthesiologists status I, II and III, elective, primary, unilateral TKA planned for spinal anesthesia with plain 0.5% bupivacaine.

Exclusion

Refusal of consent
Pregnancy
Conditions making the patient unable to fill out questionnaire online, through email or over the phone including with cognitive dysfunction, psychiatric disorder, or non-English speaking patients, or lack of internet access which would prevent post discharge follow-up electronically
Coagulopathy
Allergy to or for any other reasons cannot use Acetaminophen, Celebrex, local anesthetic bupivacaine, DEX, MPA or LB
Patients on any amounts of opioids within one month of the surgery date, any substance abuse such as regular marijuana user (more frequent than once per month)
Insulin dependent or uncontrolled diabetes defined as, day of surgery finger stick glucose \>200mg/dl, or HbA1C \> 8.0%
Peripheral Nerve Block site or systemic infection
Immune compromise (e.g., HIV, chronic glucocorticoid use)
Severe pre-existing neuropathy
TKA for indications other than osteoarthritis such as post-traumatic injury or rheumatoid arthritis, history of surgery in the ipsilateral knee joint, revision TKA or bilateral TKA
Severe hepatic or renal dysfunction (GFR \<50 ml/min)
Actual body weight \<60 kg
Patients with active or latent peptic ulcers, diverticulitis, fresh intestinal anastomoses, and non-specific ulcerative colitis

What this trial measures

  • Postoperative Knee Pain ScoreDay 1 and Day 2

    Average postoperative knee pain scores for the first two postoperative days using Visual analogue scale (VAS) pain score. Score range from 0 (no pain) to 10 (worst pain possible).

  • Postoperative opioid consumptionFrom anesthesia end time to discharge time, up to 48 hours

    In-hospital postoperative opioid consumption in oral milligram morphine equivalent (OME) will be monitored up to 48-hour between anesthesia end time and discharge time